Carleen Cullinane

Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer

Asif Noor, Jessica K Van Zuylekom, Stacey E Rudd, Kelly Waldeck, Peter D Roselt, Mohammad B Haskali, Michael P Wheatcroft, Eddie Yan, Rodney J Hicks, Carleen Cullinane, Paul S Donnelly

Journal article  |  2020  |  Journal of Medicinal Chemistry

Prostate-specific membrane antigen (PSMA) is a carboxypeptidase that is overexpressed in prostate cancer and is an excellent candi..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Clinical Cancer Research

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E Rogers, Peter Eu, Richard W Tothill, Rodney J Hicks

Journal article  |  2020  |  Scientific Reports

Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-ex..

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..

Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE is Highly Efficacious Against a Somatostatin Positive Neuroendocrine Tumor Model.

Carleen Cullinane, Charmaine M Jeffery, Peter D Roselt, Ellen M van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J Harris, Rodney J Hicks, Paul S Donnelly

Journal article  |  2020  |  Journal of Nuclear Medicine

Peptide receptor radionuclide therapy using radiolabeled octreotate is an effective treatment for somatostatin receptor 2 expressi..

First in Human Study of In-vivo Imaging of Ex-Vivo Labelled CAR T Cells with Dual PET-MR

R Singla, D Wall, S Anderson, N Zia, J Korte, L Kravets, G McKiernan, J Butler, A Gammilonghi, J Arora, M Wright, B Solomon, RJ Hicks, T Cain, P Darcy, C Cullinane, P Neeson, R Ramanathan, R Shukla, V Bansal, et al.

Conference Proceedings  |  2020  |  Cytotherapy

A Cu-64/Cu-67 bifunctional PSMA ligand as a theranostic for prostate cancer

Lachlan McInnes, Nicholas Zia, Carleen Cullinane, Jessica Van Zuylekom, Susan Jackson, Jon Stoner, Mohammad Haskali, Peter Roselt, Ellen Van Dam, Matthew Harris, Rodney Hicks, Paul Donnelly

Conference Proceedings  |  2020  |  JOURNAL OF NUCLEAR MEDICINE

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.

Jessamy Tiffen, Stuart J Gallagher, Fabian Filipp, Dilini Gunatilake, Abdullah Al Emran, Carleen Cullinane, Ken Dutton-Register, Lauren Aoude, Nick Hayward, Aniruddha Chatterjee, Euan J Rodger, Michael R Eccles, Peter Hersey

Journal article  |  2020  |  Journal of Investigative Dermatology

The histone methylase EZH2 is frequently dysregulated in melanoma and is associated with DNA methylation and silencing of genes in..

Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma

Hsin-Yi Tseng, Jan Dreyer, Abdullah Al Emran, Dilini Gunatilake, Mehdi Pirozyan, Carleen Cullinane, Ken Dutton-Regester, Helen Rizos, Nicholas K Hayward, Grant McArthur, Peter Hersey, Jessamy Tiffen, Stuart Gallagher

Journal article  |  2020  |  International Journal of Cancer